TScan Therapeutics Q1 2024 GAAP EPS $(0.32) Misses $(0.26) Estimate, Sales $566.000 Miss $3.975M Estimate
Portfolio Pulse from Benzinga Newsdesk
TScan Therapeutics reported a Q1 2024 GAAP EPS of $(0.32), missing the $(0.26) estimate, and sales of $566,000, significantly below the $3.975M estimate.
May 13, 2024 | 11:05 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
TScan Therapeutics missed Q1 2024 earnings and sales estimates, which could negatively impact investor sentiment and stock price in the short term.
Missing both earnings and sales estimates typically leads to negative investor sentiment, which can result in a decrease in stock price in the short term. The significant miss in sales estimates is particularly concerning and could lead to a more pronounced negative reaction in the market.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100